ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för PM00104. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

24 träffar

Bibliografisk träff 2024-10-30

Translating molecular insights into clinical success: alkaloid-based therapies for leukemia.

Goleij P, Tabari MAK, Rezaee A, Sanaye PM, Daglia M, Alijanzadeh D, Alsharif KF, Kumar AP, Khan H.

Naunyn Schmiedebergs Arch Pharmacol · review; journal article · DOI 10.1007/s00210-024-03540-7

Bibliografisk träff 2021-08-27

Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms.

Wu L, Ye K, Jiang S, Zhou G.

Mar Drugs · review-article; review; journal article · DOI 10.3390/md19090488

Bibliografisk träff 2016-08-18

Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone.

López-Iglesias AA, González-Méndez L, San-Segundo L, Herrero AB, Hernández-García S, Martín-Sánchez M, Gutiérrez NC, Paíno T, Avilés P, Mateos MV, San-Miguel JF, Garayoa M, Ocio EM.

Haematologica · research support, non-u.s. gov't; research-article; journal article · DOI 10.3324/haematol.2016.146076

Bibliografisk träff 2015-06-02

Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma.

Ocio EM, Oriol A, Bladé J, Teruel AI, Martín J, de la Rubia J, Gutiérrez NC, Rodríguez Díaz-Pavón J, Martínez González S, Coronado C, Fernández-García EM, Siguero Gómez M, Fernández-Teruel C, San Miguel J.

Br J Haematol · letter; clinical trial, phase ii; clinical trial, phase i · DOI 10.1111/bjh.13515

Bibliografisk träff 2014-08-15

PM00104 (Zalypsis®): a marine derived alkylating agent.

Petek BJ, Jones RL.

Molecules · review-article; review; journal article · DOI 10.3390/molecules190812328

Bibliografisk träff 2014-04-23

Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis.

Moneo V, Serelde BG, Blanco-Aparicio C, Diaz-Uriarte R, Avilés P, Santamaría G, Tercero JC, Cuevas C, Carnero A.

BMC Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1471-2407-14-281

Bibliografisk träff 2014-02-26

Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

Castellano DE, Bellmunt J, Maroto JP, Font-Pous A, Morales-Barrera R, Ghanem I, Suarez C, Martín Lorente C, Etxaniz O, Capdevila L, Coronado C, Alfaro V, Siguero M, Fernández-Teruel C, Carles J.

Cancer Chemother Pharmacol · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-014-2419-7

Bibliografisk träff 2014-02-19

Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors.

Salazar R, Calles A, Gil M, Durán I, García M, Hidalgo M, Coronado C, Alfaro V, Siguero M, Fernández-Teruel C, Prados R, Calvo E.

Invest New Drugs · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s10637-014-0072-y

Bibliografisk träff 2013-11-01

A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.

Jones RL, Ferrari S, Blay JY, Navid F, Lardelli P, Alfaro V, Siguero M, Soman N, Chawla SP.

Invest New Drugs · clinical trial, phase ii; multicenter study; journal article · DOI 10.1007/s10637-013-0037-6

Bibliografisk träff 2013-06-15

Phase II study of weekly PM00104 (ZALYPSIS(®)) in patients with pretreated advanced/metastatic endometrial or cervical cancer.

Martin LP, Krasner C, Rutledge T, Ibañes ML, Fernández-García EM, Kahatt C, Gómez MS, McMeekin S.

Med Oncol · clinical trial, phase ii; journal article · DOI 10.1007/s12032-013-0627-3

Bibliografisk träff 2013-05-25

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

Romano M, Frapolli R, Zangarini M, Bello E, Porcu L, Galmarini CM, García-Fernández LF, Cuevas C, Allavena P, Erba E, D'Incalci M.

Int J Cancer · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1002/ijc.28213

Bibliografisk träff 2013-03-02

A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.

Capdevila J, Clive S, Casado E, Michie C, Piera A, Sicart E, Carreras MJ, Coronado C, Kahatt C, Soto Matos-Pita A, Fernandez Teruel C, Siguero M, Cullell-Young M, Tabernero J.

Cancer Chemother Pharmacol · comparative study; clinical trial, phase i; journal article · DOI 10.1007/s00280-013-2119-8

Bibliografisk träff 2012-11-01

Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)).

González-Sales M, Valenzuela B, Pérez-Ruixo C, Fernández Teruel C, Miguel-Lillo B, Soto-Matos A, Pérez-Ruixo JJ.

Clin Pharmacokinet · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s40262-012-0011-z

Bibliografisk träff 2012-06-12

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.

Massard C, Margetts J, Amellal N, Drew Y, Bahleda R, Stephens P, Armand JP, Calvert H, Soria JC, Coronado C, Kahatt C, Alfaro V, Siguero M, Fernández-Teruel C, Plummer R.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s10637-012-9843-5

Bibliografisk träff 2012-04-01

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.

Yap TA, Cortes-Funes H, Shaw H, Rodriguez R, Olmos D, Lal R, Fong PC, Tan DS, Harris D, Capdevila J, Coronado C, Alfaro V, Soto-Matos A, Fernández-Teruel C, Siguero M, Tabernero JM, Paz-Ares L, de Bono JS, López-Martin JA.

Br J Cancer · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1038/bjc.2012.99

Bibliografisk träff 2011-08-01

XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids.

Feuerhahn S, Giraudon C, Martínez-Díez M, Martínez-Díez M, Bueren-Calabuig JA, Galmarini CM, Gago F, Egly JM.

Chem Biol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.chembiol.2011.06.007

Bibliografisk träff 2011-05-18

Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.

Pérez-Ruixo C, Valenzuela B, Fernández Teruel C, González-Sales M, Miguel-Lillo B, Soto-Matos A, Pérez-Ruixo JJ.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s00280-011-1644-6

Bibliografisk träff 2011-02-17

Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.

Colado E, Paíno T, Maiso P, Ocio EM, Chen X, Alvarez-Fernández S, Gutiérrez NC, Martín-Sánchez J, Flores-Montero J, San Segundo L, Garayoa M, Fernández-Lázaro D, Vidriales MB, Galmarini CM, Avilés P, Cuevas C, Pandiella A, San-Miguel JF.

Haematologica · research support, non-u.s. gov't; research-article; journal article · DOI 10.3324/haematol.2010.036400

Bibliografisk träff 2009-09-09

ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.

Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek FJ.

PLoS One · research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0006967

Bibliografisk träff 2009-07-07

Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.

Guirouilh-Barbat J, Antony S, Pommier Y.

Mol Cancer Ther · research support, n.i.h., intramural; research-article; journal article · DOI 10.1158/1535-7163.mct-09-0336

Bibliografisk träff 2009-04-11

Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines.

Leal JF, García-Hernández V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillén-Navarro MJ, Avilés P, Cuevas C, García-Fernández LF, Galmarini CM.

Biochem Pharmacol · comparative study; journal article · DOI 10.1016/j.bcp.2009.04.003

Bibliografisk träff 2008-11-19

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.

Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernández S, San-Segundo L, Vilanova D, López-Corral L, Montero JC, Hernández-Iglesias T, de Alava E, Galmarini C, Avilés P, Cuevas C, San-Miguel JF, Pandiella A.

Blood · research support, non-u.s. gov't; journal article · DOI 10.1182/blood-2008-09-177774

Bibliografisk träff 2008-10-01

Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.

Duan Z, Choy E, Jimeno JM, Cuevas Cdel M, Mankin HJ, Hornicek FJ.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1007/s00280-008-0843-2

Bibliografisk träff 2005-01-01

Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM00104, a novel antineoplastic agent, in mouse, rat, dog, and human plasma.

Yin J, Aviles P, Lee W, Ly C, Guillen MJ, Munt S, Cuevas C, Faircloth G.

Rapid Commun Mass Spectrom · comparative study; evaluation study; journal article · DOI 10.1002/rcm.1848